Abstract
The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.
| Original language | English (US) |
|---|---|
| Article number | 8 |
| Journal | Journal for ImmunoTherapy of Cancer |
| Volume | 3 |
| Issue number | 1 |
| DOIs |
|
| State | Published - Mar 24 2015 |
Fingerprint
Keywords
- Biomarkers
- Clinical trial
- Immune monitoring
- Immunotherapy
- Taskforce
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Molecular Medicine
- Oncology
- Pharmacology
- Cancer Research
Cite this
Preamble to the 2015 SITC immunotherapy biomarkers taskforce. / Butterfield, Lisa H.; Disis, Mary L.; Fox, Bernard A.; Khleif, Samir N.; Marincola, Francesco M.
In: Journal for ImmunoTherapy of Cancer, Vol. 3, No. 1, 8, 24.03.2015.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Preamble to the 2015 SITC immunotherapy biomarkers taskforce
AU - Butterfield, Lisa H.
AU - Disis, Mary L.
AU - Fox, Bernard A.
AU - Khleif, Samir N.
AU - Marincola, Francesco M.
PY - 2015/3/24
Y1 - 2015/3/24
N2 - The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.
AB - The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.
KW - Biomarkers
KW - Clinical trial
KW - Immune monitoring
KW - Immunotherapy
KW - Taskforce
UR - http://www.scopus.com/inward/record.url?scp=84977100953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977100953&partnerID=8YFLogxK
U2 - 10.1186/s40425-015-0052-6
DO - 10.1186/s40425-015-0052-6
M3 - Comment/debate
VL - 3
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
SN - 2051-1426
IS - 1
M1 - 8
ER -